Orion and Save the Children Finland announce cooperation to promote well-being of children in Finland and globally - Seite 2

Every child has the right to live as healthy as possible and to receive the best possible nutrition. Save the Children Finland ensures, through its Health & Nutrition programs, among other things, adequate nutrition for children and the treatment of malnutrition, as well as enabling their access to proper healthcare. Through Save the Children Finland`s mobile and maintained health clinics, it can be ensured that children and families in project areas in East Africa, including Sudan, receive the assistance they need. Additionally, Save the Children Finland provides parents with information on good nutrition.

"Our long-term goal is for children to grow and thrive in a safe environment, both in Finland and globally. Together with children and our partners, we improve children's lives in both everyday life and amidst crises, building a better future for them. In addition to providing immediate support and assistance to children and families, we aim to bring about sustainable positive changes and lasting improvements in children's lives," says Hanna Markkula-Kivisilta, Secretary General of Save the Children Finland.

"We warmly thank Orion for their trust in our important work and their willingness to support and be part of our international community. It is of paramount importance for us to build long-term partnerships with companies for whom responsibility means tangible actions and who, together, want to contribute to a better future for our society," Markkula-Kivisilta adds.

About Orion

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.